Bendamustine HCl was originally manufactured in East Germany (former German Democratic Republic) in 1963. In March 2008, Cephalon was approved by the U.S. Food and Drug Administration (FDA) to market this product in the United States for the treatment of chronic lymphocytic leukemia (CLL). In October 2008, the FDA approved Treanda for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that progresses during or within six months of treatment with rituximab or rituximab containing regimen. Common side effects include cytopenia, fever, nausea, diarrhea, loss of appetite, cough, and rash. Other serious side effects include allergic reactions and an increased risk of infection.